• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Alliance Fellows

2026 Alliance Fellows

The Alliance Fellows program (formerly named Global Research Ambassadors) is a virtual learning and engagement program for people impacted by ALS/MND worldwide who want to deepen their understanding of ALS/MND research, treatment development, and advocacy. Using a blended learning model that combines self-directed online content with interactive live sessions, the program helps participants build the knowledge and confidence needed to engage more meaningfully in research and advocacy conversations within the global ALS/MND community.

The program is designed to improve health literacy, strengthen global connections, and ensure that lived experience remains part of the future of ALS/MND research.

2026 Program Details

  • Delivery: Fully virtual, using Zoom and an online learning platform.
  • Duration: Four-week program delivered between September 21 and October 23 (dates tentative)
  • Structure: A blended learning approach combining self-paced learning and live interactive sessions
  • Pre-session learning: Approximately 1.5 hours of individual online learning and preparation before each live session
  • Live sessions: Nine 90-minute engaging and interactive live sessions, delivered across the four-week program. Session times will vary across time zones to support global participation and inclusivity. Sessions may be scheduled at different times throughout the day to accommodate participants from multiple regions. Recordings will also be available for those unable to attend live.
  • Learning experience: Participants will engage with expert faculty and peers through discussions, practical exercises, case studies, and collaborative activities designed to build knowledge, skills, and confidence.

Who Can Apply

You are encouraged to apply if you are:

  • Living with ALS/MND
  • A current or former caregiver
  • An ALS/MND gene carrier without a diagnosis
  • A family member
  • Another member of the ALS/MND community with a strong interest in research and advocacy

Each applicant must submit a separate application.

Applications for the 2026 Alliance Fellows Program are now closed. Thank you to everyone who applied.

Why the Program Matters

The program supports people affected by ALS/MND in building a stronger understanding of ALS/MND research and treatment development, clinical trials, scientific communication, research ethics, informed consent, and the important role lived experience plays in shaping research and advocacy.

Participants leave the program with:

  • A stronger understanding of ALS/MND research and treatment development
  • Greater confidence discussing scientific developments
  • Practical tools for advocacy and community engagement
  • Connections with researchers, clinicians, and peers from around the world
  • Recognition as an Alliance Fellow

Participants who complete the program receive a certificate of completion, an Alliance Fellow social media badge, recognition through Alliance communications, and opportunities to continue engaging through the Global ALS/MND Experience Network (GAMEN).

One of the program’s greatest strengths is the global community it creates — connecting people affected by ALS/MND across countries, experiences, and perspectives.

Who Should Apply?

When people affected by ALS/MND are included in research conversations, it leads to stronger advocacy, better understanding of community priorities, and more meaningful research outcomes.

You may be a strong fit for the program if you:

  • Have a personal connection to ALS/MND
  • Want to better understand ALS/MND research and treatment development
  • Are interested in advocacy or research engagement
  • Are willing to actively participate in discussions and learning activities
  • Want to connect with others in the global ALS/MND community

To participate, you will need a device with internet access and a webcam, time to attend most live sessions or watch recordings, and a willingness to learn and contribute to discussions.

If selected, participants are expected to review materials in advance, participate actively in sessions, and share what they learn with their communities following the program.

Primary Sidebar

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Mike Cels, Canada

    Mike Cels, Canada

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Lombana, Spain

    Lombana, Spain

  • Daniel Hare, USA

    Daniel Hare, USA

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Maria Santos Garcia Tellez, Mexico

    Maria Santos Garcia Tellez, Mexico

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Phil Rossall, UK

    Phil Rossall, UK

  • Rosie Riley, USA

    Rosie Riley, USA

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Marcelo Farinelli, Brazil

    Marcelo Farinelli, Brazil

  • Rolf Mauch, Switzerland

    Rolf Mauch, Switzerland

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Hiroshi Matsuyama, Japan

    Hiroshi Matsuyama, Japan

  • JP

    JP

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Denis Blais, Canada

    Denis Blais, Canada

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • David Solomon, UK

    David Solomon, UK

  • Ailsa Malcolm-Hutton, UK

    Ailsa Malcolm-Hutton, UK

  • Olga, Argentina

    Olga, Argentina

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Gudjon Sigurdsson, Iceland

    Gudjon Sigurdsson, Iceland

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Xian-Zhang Niu, China

    Xian-Zhang Niu, China

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

  • Josée Kolijn-de Man, Netherlands

    Josée Kolijn-de Man, Netherlands

  • Mark Miller, UK

    Mark Miller, UK

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Mikey Stone, ALS

    Mikey Stone, ALS

  • Claudette Sturk, Canada

    Claudette Sturk, Canada
    Picture2

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login